[1] Lianidou ES, Strati A, Markou A.Circulating tumor cells as promising novel biomarkers in solid cancers[J]. Crit Rev Clin Lab Sci,2014,51(3):160-171.
[2] Yang MH, Imrali A, Heeschen C.Circulating cancer stem cells: the importance to select[J]. Chin J Cancer Res,2015,27(5):437-449.
[3] Hyun KA, Kim J, Gwak H, et al.Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics[J]. Analyst,2016,141(2):382-392.
[4] Liu JF, Kindelberger D, Doyle C, et al.Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients[J]. Gynecol Oncol,2013, 131(2):352-356.
[5] Chaffer CL, Weinberg RA.A perspective on cancer cell metastasis[J]. Science,2011,331(6024):1559-1564.
[6] Gradilone A, Raimondi C, Nicolazzo C, et al.Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal[J]. J Cell Mol Med,2011, 15(5):1066-1070.
[7] Raimondi C, Gradilone A, Naso G, et al.Clinical utility of circulating tumor cell counting through CellSearch: the dilemma of a concept suspended in Limbo[J]. Onco Targets Ther,2014,7:619-625.
[8] Harouaka RA, Nisic M, Zheng SY.Circulating tumor cell enrichment based on physical properties[J]. J Lab Autom,2013,18(6):455-468.
[9] Khamenehfar A, Li PC.Microfluidic devices for circula-ting tumor cells isolation and subsequent analysis[J]. Curr Pharm Biotechnol,2016,17(9):810-821.
[10] Mohamed H, Murray M, Turner JN, et al.Isolation of tumor cells using size and deformation[J]. J Chromatogr A,2009,1216(47):8289-8295.
[11] Bhagat AA, Hou HW, Li LD, et al.Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation[J]. Lab Chip,2011,11(11):1870-1878.
[12] Vona G, Sabile A, Louha M, et al.Isolation by size of epi-thelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells[J]. Am J Pathol,2000,156(1):57-63.
[13] Farace F, Massard C, Vimond N, et al.A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas[J]. Br J Cancer,2011,105(6):847-853.
[14] Chen J, Cao SW, Cai Z, et al.Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients[J]. Cancer Biomark,2017,20(4):487-498.
[15] Zhao S, Liu H, Liu Y, et al.miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells[J]. Cancer Lett,2013,333(2):253-260.
[16] Gkountela S, Aceto N.Stem-like features of cancer cells on their way to metastasis[J]. Biol Direct,2016,11:33.
[17] Baccelli I, Schneeweiss A, Riethdorf S, et al.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay[J]. Nat Biotechnol,2013,31(6):539-544.
[18] Meng S, Tripathy D, Frenkel EP, et al.Circulating tumor cells in patients with breast cancer dormancy[J]. Clin Cancer Res,2004,10(24):8152-8162.
[19] Friedlander TW, Ngo VT, Dong H, et al.Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer[J]. Int J Cancer,2014,134(10):2284-2293.
[20] Pearl ML, Dong H, Zhao Q, et al.iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer[J]. Gynecol Oncol,2017,147(2):426-432.
[21] Ramirez JM, Fehm T, Orsini M, et al.Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients[J]. Clin Chem,2014,60(1):214-221.
[22] Pantel K, Alix-Panabières C.Functional studies on via-ble circulating tumor cells[J]. Clin Chem,2016,62(2):328-334.
[23] Theodoropoulos PA, Polioudaki H, Agelaki S, et al.Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer[J]. Cancer Lett,2010,288(1):99-106.
[24] Kantara C, O'Connell MR, Luthra G, et al. Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis[J]. Lab Invest,2015,95(1):100-112.
[25] Heitzer E, Auer M, Gasch C, et al.Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing[J]. Cancer Res,2013,73(10):2965-2975.
[26] de Gregorio A, Friedl TWP, Huober J, et al. Discordance in human epidermal growth gactor receptor 2 (HER2) phenotype between primary tumor and circulating tumor cells in women with HER2-negative metastatic breast cancer[J]. JCO Precision Oncology, 2017,1:12.
·专家论坛·
27 精准医学时代遗传性疾病的分子诊断
28 李牛, 王剑
29 (上海交通大学医学院附属上海儿童医学中心分子诊断实验室,上海 200127)
30 摘要:
31 关键词:遗传性疾病; 精准医学; 分子诊断; 高通量测序; 挑战
32 中图分类号:R715.5 文献识别码:A 文章编号:1671-2870(2018)02-0136-05
33 DOI:10.OI:10.16150/j.1671-2870.2018.02.003
34 Title
35 Zuozhe
36 Danwei
37 Abstract
38 keywords
39 [参考文献]
[1] Boycott KM, Rath A, Chong JX, et al.International coo-peration to enable the diagnosis of all rare genetic di-seases[J]. Am J Hum Genet,2017,100(5):695-705.
[2] 钱欣, 罗玉琴, 徐晓姹, 等. 2619例高龄孕妇羊水细胞染色体核型分析[J]. 中华医学遗传学杂志,2009,26(6):712-713.
[3] 张鼎, 胡小梅, 胡爱武. 荧光原位杂交技术及其在遗传学中的应用进展[J]. 中华全科医学,2010,8(6):762-764.
[4] Shen Y, Wu BL.Microarray-based genomic DNA profi-ling technologies in clinical molecular diagnostics[J]. Clin Chem,2009,55(4):659-669.
[5] Hu L, Yao X, Huang H, et al.Clinical significance of germline copy number variation in susceptibility of human diseases[J]. J Genet Genomics,2018,45(1):3-12.
[6] Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification[J]. Nucleic Acids Res,2002,30(12):e57.
[7] Sanger F, Nicklen S, Coulson AR.DNA sequencing with chain-terminating inhibitors[J]. Proc Natl Acad Sci U S A,1977,74(12):5463-5467.
[8] Hehir-Kwa JY, Claustres M, Hastings RJ, et al.Towards a European consensus for reporting incidental findings during clinical NGS testing[J]. Eur J Hum Genet,2015, 23(12):1601-1606.
[9] Meienberg J, Bruggmann R, Oexle K, et al.Clinical sequencing: is WGS the better WES?[J]. Hum Genet,2016,135(3):359-362.
[10] Retterer K, Juusola J, Cho MT, et al.Clinical application of whole-exome sequencing across clinical indications[J]. Genet Med,2016,18(7):696-704.
[11] Caspar SM, Dubacher N, Kopps AM, et al.Clinical sequencing: From raw data to diagnosis with lifetime value[J]. Clin Genet,2018,93(3):508-519.
[12] Byron SA, van Keuren-Jensen KR, Engelthaler DM, et al. Translating RNA sequencing into clinical diagnostics: opportunities and challenges[J]. Nat Rev Genet,2016,17(5):257-271.
[13] Kremer LS, Wortmann SB, Prokisch H. "Transcriptomics": molecular diagnosis of inborn errors of metabolism via RNA-sequencing[J/OL]. Inherit Metab Dis,2018-01-25[2018-03-19]. https://www.ncbi.nlm.nih.gov/pubmed/29372369.
[14] Kimble DC, Lach FP, Gregg SQ, et al.A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families[J]. Hum Mutat,2018,39(2):237-254.
[15] Miller DT, Adam MP, Aradhya S, et al.Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies[J]. Am J Hum Genet,2010,86(5):749-764.
[16] Hu X, Li N, Xu Y, et al. Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: the China experience[J/OL]. Genet Med,2017-11-02[2018-03-19].https://www.ncbi.nlm.nih.gov/pubmed/29095814.
[17] Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing[J/OL]. Genet Med,2018-03-22[2018-04-09].https://www.ncbi.nlm.nih.gov/pubmed/29565419.
[18] Posey JE, Harel T, Liu P, et al.Resolution of disease phenotypes resulting from multilocus genomic variation[J]. N Engl J Med,2017,376(1):21-31.
[19] Kalia SS, Adelman K, Bale SJ, et al.Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics[J]. Genet Med,2017,19(2):249-255.
[20] Kearney HM, Thorland EC, Brown KK, et al.American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants[J]. Genet Med,2011,13(7):680-685.
[21] Richards S, Aziz N, Bale S, et al.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med,2015,17(5):405-424.
[22] National Society of Genetic Counselors' Definition Task Force, Resta R, Biesecker BB, et al. A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report[J]. J Genet Couns,2006,15(2):77-83.
[23] Tarailo-Graovac M, Shyr C, Ross CJ, et al.Exome sequencing and the management of neurometabolic disorders[J]. N Engl J Med,2016,374(23):2246-2255. |
